A Phase 2 interventional study of BR5402A and BR5402A-1 in Schizophrenia, sponsored by Boryung Pharmaceutical Co., Ltd. Recruiting at 2 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Schizophrenia with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Schizophrenia · Korea, Republic of.
Among the 112 studies in Schizophrenia with a site in Korea, Republic of, this one is the 60th largest by planned enrollment of the 89 interventional ones that give a count, is the only one that started in 2025, is one of 8 in phase 2, and was the 111th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →2 of the 112 studies in Schizophrenia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19–60
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 41 · Phase 4 27
First in 2002; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 291 across the 89 interventional studies, 100 across the 23 observational. Of the 92 that completed or were terminated, 47 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 112 have an industry lead sponsor. The 10 most frequent:
Boryung Pharmaceutical Co., Ltd is the lead sponsor of 143 studies on the registry; 23 are open to participants now.
Boryung Pharmaceutical Co., Ltd has 1 study filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
2 of the studies in Schizophrenia with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07755605Samsung Medical CenterDigital Therapeutics for Social Cognitive Function in Schizophrenia Spectrum Disorder | 2026-12 |
| NCT06821945Boryung Pharmaceutical Co., LtdA Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 112 studies in Schizophrenia with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this clinical trial is to evaluate the safety and efficacy of olanzapine titration schedule in patients with schizophrenia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BR5402A · Drug: BR5402B · Drug: BR5402C · Drug: BR5402C-1 · Drug: BR5402D · Drug: BR5402D-1
Drug: BR5402A-1 · Drug: BR5402B-1 · Drug: BR5402C · Drug: BR5402C-1 · Drug: BR5402D
Subjects take the investigational products once a day
Subjects take the investigational products once a day
Also known as: Placebo of BR5402A
Subjects take the investigational products once a day
Subjects take the investigational products once a day
Also known as: Placebo of BR5402B
Subjects take the investigational products once a day
Subjects take the investigational products once a day
Also known as: Placebo of BR5402C
Subjects take the investigational products once a day
Subjects take the investigational products once a day
Also known as: Placebo of BR5402D
The mean change of PANSS(Positive and Negative Syndrome Scale) total score
Time frame: 1, 2, 3, 5, 9 weeks from baseline(Visit 2)
Incidence of treatment-emergent adverse events
Time frame: From the administration of investigational products prescribed at baseline(Visit 2) to 11 weeks(Visit 8)
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's planned 24 months is above that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boryung Pharmaceutical Co., Ltd →